Roles of histone acetylation sites in cardiac hypertrophy and heart failure

被引:13
|
作者
Funamoto, Masafumi [1 ]
Imanishi, Masaki [2 ]
Tsuchiya, Koichiro [2 ]
Ikeda, Yasumasa [1 ]
机构
[1] Tokushima Univ, Inst Biomed Sci, Dept Pharmacol, Grad Sch, Tokushima, Japan
[2] Tokushima Univ, Inst Biomed Sci, Dept Med Pharmacol, Grad Sch, Tokushima, Japan
来源
关键词
epigenetics; histone post-translational modification; cardiac hypertrophy; heart failure; acetylation; ACETYLTRANSFERASE ACTIVITY; EPIGENETIC REGULATION; DEACETYLASE; P300; METHYLATION; RESPONSES; COMPLEX; GATA4; ACTS;
D O I
10.3389/fcvm.2023.1133611
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure results from various physiological and pathological stimuli that lead to cardiac hypertrophy. This pathological process is common in several cardiovascular diseases and ultimately leads to heart failure. The development of cardiac hypertrophy and heart failure involves reprogramming of gene expression, a process that is highly dependent on epigenetic regulation. Histone acetylation is dynamically regulated by cardiac stress. Histone acetyltransferases play an important role in epigenetic remodeling in cardiac hypertrophy and heart failure. The regulation of histone acetyltransferases serves as a bridge between signal transduction and downstream gene reprogramming. Investigating the changes in histone acetyltransferases and histone modification sites in cardiac hypertrophy and heart failure will provide new therapeutic strategies to treat these diseases. This review summarizes the association of histone acetylation sites and histone acetylases with cardiac hypertrophy and heart failure, with emphasis on histone acetylation sites.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Alterations in calcium handling in cardiac hypertrophy and heart failure
    Balke, CW
    Shorofsky, SR
    CARDIOVASCULAR RESEARCH, 1998, 37 (02) : 290 - 299
  • [32] The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure
    Liao, Hai-Han
    Jia, Xu-Hui
    Liu, Huang-Jun
    Yang, Zheng
    Tang, Qi-Zhu
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (11) : 1677 - 1686
  • [33] Distinct functions of junD in cardiac hypertrophy and heart failure
    Ricci, R
    Eriksson, U
    Oudit, GY
    Eferl, R
    Akhmedov, A
    Sumara, I
    Sumara, G
    Kassiri, Z
    David, JP
    Bakiri, L
    Sasse, B
    Idarraga, MH
    Rath, M
    Kurz, D
    Theussl, HC
    Perriard, JC
    Backx, P
    Penninger, JM
    Wagner, EF
    GENES & DEVELOPMENT, 2005, 19 (02) : 208 - 213
  • [34] Metabolic remodelling in cardiac hypertrophy - a factor in heart failure?
    Seymour, AML
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 37 (01) : 351 - 351
  • [35] Cardiac metabolism in hypertrophy and heart failure: implications for therapy
    Siddiqi, N.
    Singh, S.
    Beadle, R.
    Dawson, D.
    Frenneaux, M.
    HEART FAILURE REVIEWS, 2013, 18 (05) : 595 - 606
  • [36] Alterations in mitochondrial function in cardiac hypertrophy and heart failure
    Osterholt, Moritz
    Nguyen, T. Dung
    Schwarzer, Michael
    Doenst, Torsten
    HEART FAILURE REVIEWS, 2013, 18 (05) : 645 - 656
  • [37] β-adrenergic receptor desensitization in cardiac hypertrophy and heart failure
    Dong-Ju Choi
    Howard A. Rockman
    Cell Biochemistry and Biophysics, 1999, 31 : 321 - 329
  • [38] β-adrenergic receptor desensitization in cardiac hypertrophy and heart failure
    Choi, DJ
    Rockman, HA
    CELL BIOCHEMISTRY AND BIOPHYSICS, 1999, 31 (03) : 321 - 329
  • [39] Cardiac metabolism in hypertrophy and heart failure: implications for therapy
    N. Siddiqi
    S. Singh
    R. Beadle
    D. Dawson
    M. Frenneaux
    Heart Failure Reviews, 2013, 18 : 595 - 606
  • [40] Arrhythmogenesis in cardiac hypertrophy and heart failure - experimental findings
    Milberg, P.
    Pott, C.
    Eckardt, L.
    Breithardt, G.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2008, 133 (50) : S285 - S289